Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy

Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs. Three drug delivery technologies related to albumin have been developed, which includ...

Full description

Saved in:
Bibliographic Details
Published inChemical Society reviews Vol. 45; no. 5; pp. 1432 - 1456
Main Authors Liu, Zhibo, Chen, Xiaoyuan
Format Journal Article
LanguageEnglish
Published England 07.03.2016
Subjects
Albumins
Bright plating
chemistry
Coupling (molecular)
Diagnosis
Drug Delivery Systems
Drugs
encapsulation
human serum albumin
Humans
nanoparticles
Peptides
Pharmaceutical Preparations - chemistry
pharmacokinetics
Platforms
Proteins
Serum Albumin - chemistry
therapeutics
Online AccessGet full text

Cover

More Information
Summary:Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs. Three drug delivery technologies related to albumin have been developed, which include the coupling of low-molecular weight drugs to exogenous or endogenous albumin, conjugating bioactive proteins by albumin fusion technology (AFT), and encapsulation of drugs into albumin nanoparticles. This review article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mainstream chemical strategies of developing HSA binding molecules for coupling with drug molecules. Moreover, we also concisely condense the recent progress of the most important clinical applications of HSA-binding platforms, and specify the current challenges that need to be met for a bright future of HSA-binding. Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs.
Bibliography:Zhibo (Zippo) Liu received his BS in Chemistry from Nanjing University in 2010, and PhD in Chemistry from the University of British Columbia in 2014. Under the supervision of Drs David M. Perrin, Kuo-Shyan Lin, and François Bénard, he developed a broadly applicable one-step 18F-labeling method based on a novel organotrifluoroborate. Right after graduation, he joined the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at National Institutes of Health (NIH) as a postdoctoral research fellow under the supervision of Dr Xiaoyuan (Shawn) Chen. His research focuses on developing albumin-binding imaging probes as well as utilizing boramino acid to identify tumor from inflammation for early cancer diagnosis.
Xiaoyuan (Shawn) Chen received his PhD in chemistry from the University of Idaho in 1999. After being a faculty member at the University of Southern California and Stanford University, he joined the Intramural Research Program of the NIBIB in 2009 as a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN). Dr Chen has published over 500 papers (H-index = 90) and numerous books and book chapters. He sits on the editorial board of over 10 peer-reviewed journals and is the founding editor of the journal Theranostics. His lab focuses on developing molecular imaging probes and nanotechnologies for early diagnosis of disease, monitoring therapy responses, and guiding drug discovery/development.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0306-0012
1460-4744
1460-4744
DOI:10.1039/c5cs00158g